[Cutaneous reactions to treatment with recombinant human erythropoietin].
Recently, recombinant human erythropoietin produced by gene technology has become available in the treatment of renal anemia in dialysis patients. A papulous skin reaction as well as a generally increased pruritus has been reported in several patients following 2 to 3 months of treatment. Following a course of recurrence lasting several weeks, the skin changes cleared up spontaneously. In one female patient, treatment was discontinued due to skin reaction.
Schröder-Kolb
B
B
Nephrologischen Zentrum Niedersachsen, Hann.-Münden.
D000740:Anemia / Q000628:therapy*; D003875:Drug Eruptions / Q000209:etiology*; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin
Kutane Reaktionen auf eine Therapie mit rekombinantem humanem Erythropoietin.